Predictive and Prognostic Factors in HCC Patients Treated with Sorafenib
Published 2019 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Predictive and Prognostic Factors in HCC Patients Treated with Sorafenib
Authors
Keywords
-
Journal
Medicina-Lithuania
Volume 55, Issue 10, Pages 707
Publisher
MDPI AG
Online
2019-10-21
DOI
10.3390/medicina55100707
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- The Role of Nrf2 in Liver Disease: Novel Molecular Mechanisms and Therapeutic Approaches
- (2019) Dongwei Xu et al. Frontiers in Pharmacology
- Changes in the neutrophil-to-lymphocyte ratio predict the prognosis of patients with advanced hepatocellular carcinoma treated with sorafenib
- (2019) Young Mi Hong et al. EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY
- Genome-wide copy number alteration and VEGFA amplification of circulating cell-free DNA as a biomarker in advanced hepatocellular carcinoma patients treated with Sorafenib
- (2019) Chung Ryul Oh et al. BMC CANCER
- MiR-122 Targets SerpinB3 and Is Involved in Sorafenib Resistance in Hepatocellular Carcinoma
- (2019) Cristian Turato et al. Journal of Clinical Medicine
- Relative Efficacy of Systemic Treatments for Patients with Advanced Hepatocellular Carcinoma According to Viral Status: A Systematic Review and Network Meta-Analysis
- (2019) Jisun Park et al. Targeted Oncology
- Differential expression profiling of long non-coding RNA GAS5 and miR-126-3p in human cancer cells in response to sorafenib
- (2019) Teresa Faranda et al. Scientific Reports
- A Phase 2 Study of Galunisertib (TGF-β1 Receptor Type I Inhibitor) and Sorafenib in Patients With Advanced Hepatocellular Carcinoma
- (2019) R.K. Kelley et al. Clinical and Translational Gastroenterology
- ANGPT2 and NOS3 Polymorphisms and Clinical Outcome in Advanced Hepatocellular Carcinoma Patients Receiving Sorafenib
- (2019) Giorgia Marisi et al. Cancers
- Verteporfin-induced lysosomal compartment dysregulation potentiates the effect of sorafenib in hepatocellular carcinoma
- (2019) Jacopo Gavini et al. Cell Death & Disease
- Novel biomarker-based model for the prediction of sorafenib response and overall survival in advanced hepatocellular carcinoma: a prospective cohort study
- (2018) Hwi Young Kim et al. BMC CANCER
- The role of inflammatory cytokines and tumor associated macrophages (TAMs) in microenvironment of pancreatic cancer
- (2018) Saeed Farajzadeh Valilou et al. CYTOKINE & GROWTH FACTOR REVIEWS
- Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial
- (2018) Masatoshi Kudo et al. LANCET
- The BRAF Status May Predict Response to Sorafenib in Gastrointestinal Stromal Tumors Resistant to Imatinib, Sunitinib, and Regorafenib: Case Series and Review of the Literature
- (2018) Caspar Franck et al. DIGESTION
- Multicenter Prospective Study of Angiogenesis Polymorphism Validation in HCC Patients Treated with Sorafenib. An INNOVATE Study Protocol
- (2018) Andrea Casadei Gardini et al. TUMORI
- A Phase Ib, Open‐Label Study of Dalantercept, an Activin Receptor‐Like Kinase 1 Ligand Trap, plus Sorafenib in Advanced Hepatocellular Carcinoma
- (2018) Ghassan K. Abou‐Alfa et al. ONCOLOGIST
- Dysregulation of Nrf2 in Hepatocellular Carcinoma: Role in Cancer Progression and Chemoresistance
- (2018) Azhwar Raghunath et al. Cancers
- Metformin and insulin impact on clinical outcome in patients with advanced hepatocellular carcinoma receiving sorafenib: Validation study and biological rationale
- (2017) Andrea Casadei Gardini et al. EUROPEAN JOURNAL OF CANCER
- Immunotherapy for colorectal cancer: where are we heading?
- (2017) Debora Basile et al. EXPERT OPINION ON BIOLOGICAL THERAPY
- Liquid dynamic medicine and N-of-1 clinical trials: a change of perspective in oncology research
- (2017) Nicola Silvestris et al. JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
- Prognostic factors and predictors of sorafenib benefit in patients with hepatocellular carcinoma: Analysis of two phase III studies
- (2017) Jordi Bruix et al. JOURNAL OF HEPATOLOGY
- An Explorative Analysis for the Role of Serum miR-10b-3p Levels in Predicting Response to Sorafenib in Patients with Advanced Hepatocellular Carcinoma
- (2017) Eileen L. Yoon et al. JOURNAL OF KOREAN MEDICAL SCIENCE
- Validation of a Simple Scoring System to Predict Sorafenib Effectiveness in Patients with Hepatocellular Carcinoma
- (2017) Giovan Giuseppe Di Costanzo et al. Targeted Oncology
- Neutrophil-to-lymphocyte ratio predicts survival in European patients with hepatocellular carcinoma administered sorafenib
- (2017) Alberto Lué et al. Oncotarget
- Immunotherapeutic approaches for hepatocellular carcinoma
- (2017) Vito Longo et al. Oncotarget
- Hand-foot skin reaction is a beneficial indicator of sorafenib therapy for patients with hepatocellular carcinoma: a systemic review and meta-analysis
- (2017) Ping Wang et al. Expert Review of Gastroenterology & Hepatology
- Efficacy of sorafenib in BRAF-mutated non-small-cell lung cancer (NSCLC) and no response in synchronous BRAF wild type-hepatocellular carcinoma: a case report
- (2016) Andrea Casadei Gardini et al. BMC CANCER
- Circulating exosomes and exosomal microRNAs as biomarkers in gastrointestinal cancer
- (2016) R Nedaeinia et al. CANCER GENE THERAPY
- MicroRNA-122 confers sorafenib resistance to hepatocellular carcinoma cells by targeting IGF-1R to regulate RAS/RAF/ERK signaling pathways
- (2016) Yanmin Xu et al. CANCER LETTERS
- Angiogenesis polymorphisms profile in the prediction of clinical outcome of advanced HCC patients receiving sorafenib: Combined analysis of VEGF and HIF-1α—Final results of the ALICE-2 study.
- (2016) Luca Faloppi et al. JOURNAL OF CLINICAL ONCOLOGY
- Observational registry of sorafenib use in clinical practice across Child-Pugh subgroups: The GIDEON study
- (2016) Jorge A. Marrero et al. JOURNAL OF HEPATOLOGY
- Angiogenesis in pancreatic ductal adenocarcinoma: A controversial issue
- (2016) Vito Longo et al. Oncotarget
- MicroRNAs for the Prediction of Early Response to Sorafenib Treatment in Human Hepatocellular Carcinoma
- (2016) Naoshi Nishida et al. Liver Cancer
- Effects of metformin on clinical outcome in diabetic patients with advanced HCC receiving sorafenib
- (2015) Andrea Casadei Gardini et al. EXPERT OPINION ON PHARMACOTHERAPY
- Hepatocellular carcinoma treatment over sorafenib: epigenetics, microRNAs and microenvironment. Is there a light at the end of the tunnel?
- (2015) Antonio Gnoni et al. EXPERT OPINION ON THERAPEUTIC TARGETS
- Linifanib Versus Sorafenib in Patients With Advanced Hepatocellular Carcinoma: Results of a Randomized Phase III Trial
- (2015) Calin Cainap et al. JOURNAL OF CLINICAL ONCOLOGY
- Targeted DNA and RNA sequencing of fine-needle biopsy FFPE specimens in patients with unresectable hepatocellular carcinoma treated with sorafenib
- (2015) Kazuko Sakai et al. Oncotarget
- MicroRNA in pancreatic adenocarcinoma: predictive/prognostic biomarkers or therapeutic targets?
- (2015) Oronzo Brunetti et al. Oncotarget
- MiR-21 mediates sorafenib resistance of hepatocellular carcinoma cells by inhibiting autophagy via the PTEN/Akt pathway
- (2015) Changjun He et al. Oncotarget
- MicroRNA-423-5p Promotes Autophagy in Cancer Cells and Is Increased in Serum From Hepatocarcinoma Patients Treated With Sorafenib
- (2015) Paola Stiuso et al. Molecular Therapy-Nucleic Acids
- Metformin and Cancer Risk and Mortality: A Systematic Review and Meta-analysis Taking into Account Biases and Confounders
- (2014) S. Gandini et al. Cancer Prevention Research
- Systemic Immune-Inflammation Index Predicts Prognosis of Patients after Curative Resection for Hepatocellular Carcinoma
- (2014) B. Hu et al. CLINICAL CANCER RESEARCH
- Hepatocellular Carcinoma: Reasons for Phase III Failure and Novel Perspectives on Trial Design
- (2014) J. M. Llovet et al. CLINICAL CANCER RESEARCH
- VEGF and VEGFR genotyping in the prediction of clinical outcome for HCC patients receiving sorafenib: The ALICE-1 study
- (2014) Mario Scartozzi et al. INTERNATIONAL JOURNAL OF CANCER
- Early dermatologic adverse events predict better outcome in HCC patients treated with sorafenib
- (2014) Maria Reig et al. JOURNAL OF HEPATOLOGY
- Pretreatment MicroRNA Level and Outcome in Sorafenib-treated Hepatocellular Carcinoma
- (2014) Benedek Gyöngyösi et al. JOURNAL OF HISTOCHEMISTRY & CYTOCHEMISTRY
- MicroRNA-425-3p predicts response to sorafenib therapy in patients with hepatocellular carcinoma
- (2014) Valentina Vaira et al. LIVER INTERNATIONAL
- Human and Mouse VEGFA-Amplified Hepatocellular Carcinomas Are Highly Sensitive to Sorafenib Treatment
- (2014) E. Horwitz et al. Cancer Discovery
- Changes in plasma vascular endothelial growth factor at 8 weeks after sorafenib administration as predictors of survival for advanced hepatocellular carcinoma
- (2013) Kaoru Tsuchiya et al. CANCER
- The Noncytotoxic Dose of Sorafenib Sensitizes Bel-7402/5-FU Cells to 5-FU by Down-Regulating 5-FU-Induced Nrf2 Expression
- (2013) Suna Zhou et al. DIGESTIVE DISEASES AND SCIENCES
- Early increase in α-fetoprotein for predicting unfavorable clinical outcomes in patients with advanced hepatocellular carcinoma treated with sorafenib
- (2013) Takahide Nakazawa et al. EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY
- Correlation of skin toxicity and hypertension with clinical benefit in advanced hepatocellular carcinoma patients treated with sorafenib
- (2013) Sun Young Shin et al. INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS
- Brivanib Versus Sorafenib As First-Line Therapy in Patients With Unresectable, Advanced Hepatocellular Carcinoma: Results From the Randomized Phase III BRISK-FL Study
- (2013) Philip J. Johnson et al. JOURNAL OF CLINICAL ONCOLOGY
- Sorafenib in patients with Child-Pugh class A and B advanced hepatocellular carcinoma: a prospective feasibility analysis
- (2012) T. Pressiani et al. ANNALS OF ONCOLOGY
- Serum Insulin-Like Growth Factor-1 Levels Predict Outcomes of Patients with Advanced Hepatocellular Carcinoma Receiving Antiangiogenic Therapy
- (2012) Y.-Y. Shao et al. CLINICAL CANCER RESEARCH
- FGF3/FGF4 amplification and multiple lung metastases in responders to sorafenib in hepatocellular carcinoma
- (2012) Tokuzo Arao et al. HEPATOLOGY
- Skin toxicities and survival in advanced hepatocellular carcinoma patients treated with sorafenib
- (2012) Taiga Otsuka et al. HEPATOLOGY RESEARCH
- Hepatocellular carcinoma
- (2012) Alejandro Forner et al. LANCET
- Diarrhea Is a Positive Outcome Predictor for Sorafenib Treatment of Advanced Hepatocellular Carcinoma
- (2012) Ronald Koschny et al. ONCOLOGY
- Safety and efficacy of sorafenib in hepatocellular carcinoma: the impact of the Child-Pugh score
- (2011) A. Hollebecque et al. ALIMENTARY PHARMACOLOGY & THERAPEUTICS
- Field-practice study of sorafenib therapy for hepatocellular carcinoma: A prospective multicenter study in Italy
- (2011) Massimo Iavarone et al. HEPATOLOGY
- Predicting the treatment effect of sorafenib using serum angiogenesis markers in patients with hepatocellular carcinoma
- (2011) Koji Miyahara et al. JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY
- High concordance of BRAF status between primary colorectal tumours and related metastatic sites: implications for clinical practice
- (2010) D. Santini et al. ANNALS OF ONCOLOGY
- Early alpha-fetoprotein response predicts treatment efficacy of antiangiogenic systemic therapy in patients with advanced hepatocellular carcinoma
- (2010) Yu-Yun Shao et al. CANCER
- Safety and efficacy of sunitinib in patients with advanced hepatocellular carcinoma: an open-label, multicentre, phase II study
- (2009) Sandrine Faivre et al. LANCET ONCOLOGY
- Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial
- (2008) Ann-Lii Cheng et al. LANCET ONCOLOGY
- Sorafenib in Advanced Hepatocellular Carcinoma
- (2008) Josep M. Llovet et al. NEW ENGLAND JOURNAL OF MEDICINE
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search